Novo Nordisk highlights several limitations of study linking Ozempic and Wegovy to sight loss

The study is not designed to show a causal relationship with the eye condition, the pharmaceutical company points out.
Photo: Sergei Gapon
Photo: Sergei Gapon
by MARKETWIRE ‎

Novo Nordisk sees a number of methodological limitations associated with the study that suggests a risk that Novo Nordisk’s best-selling diabetes 2 drug Ozempic and weight loss drug Wegovy are associated a rare type of vision loss.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading